Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson C, Davenport M, Schaefer T, Wink L, Pedapati E, Sweeney J, Fitzpatrick S, Brown W, Budimirovic D, Hagerman R, Hessl D, Kaufmann W, Berry-Kravis E. Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal Of Neurodevelopmental Disorders 2017, 9: 7. PMID: 28616096, PMCID: PMC5467059, DOI: 10.1186/s11689-017-9186-9.Peer-Reviewed Original ResearchClinical trial rationaleCurrent prescribing practicesDrug targetsAppropriate outcome measuresClinical trial designTreatment development effortsFXS animal modelsNumerous potential drug targetsTrial rationaleGABAergic neurotransmissionPrescribing practicesSyndrome pathophysiologyClinical trialsOutcome measuresTrial designAnimal modelsDrug approachSingle gene disordersPotential drug targetsTreatment developmentPharmacotherapyDrugsPathophysiologyTrial execution